Intravenous magnesium sulphate vs placebo
HRQoL score (Child‐reported PedsQL sickle cell disease module) at 1 week · people with sickle cell disease
1 finding from 1 review
- no estimate extracted1 study · 202 participantsLow
Findings
What do systematic reviews say?
450 questions · 474 findings · 58 reviews
No studies found 96 · 20.3%GRADE not reported 49 · 10.3%Very low 102 · 21.5%Low 110 · 23.2%Moderate 77 · 16.2%High 40 · 8.4%
Intravenous magnesium sulphate vs placebo
Length of hospital stay · people with sickle cell disease
1 finding from 1 review
- no estimate extracted1 study · 104 participantsLow
Intravenous magnesium sulphate vs placebo
Hypotension · people with sickle cell disease
Intravenous magnesium sulphate showed no clear difference in adverse effects: hypotension compared with placebo (low certainty).
1 finding from 1 review
- RR 2.57 [0.5, 13.08]2 studies · 306 participantsLow
Intravenous magnesium sulphate vs placebo
Adverse effects: warmth at infusion site · people with sickle cell disease
Intravenous magnesium sulphate may leads to higher adverse effects: warmth at infusion site compared with placebo (low certainty).
1 finding from 1 review
- RR 13.26 [3.23, 54.4]1 study · 202 participantsLow
(RCT) Safe intravenous systems vs regular systems
Number of reported sharps injuries, level · preventing percutaneous exposure injuries caused by needles in healthcare personnel
1 finding from 1 review
- Devices for preventing percutaneous exposure injuries caused by needles in healthcare personnel 2017 · Cochrane Headline outcomes onlyno estimate extracted2 studies · 2 participantsVery low
(RCT) Safe intravenous systems vs regular systems
Number of reported sharps injuries, slope · preventing percutaneous exposure injuries caused by needles in healthcare personnel
1 finding from 1 review
- Devices for preventing percutaneous exposure injuries caused by needles in healthcare personnel 2017 · Cochrane Headline outcomes onlyno estimate extracted2 studies · 2 participantsVery low
(RCT) Safe intravenous systems vs regular systems
Needlestick injuries · preventing percutaneous exposure injuries caused by needles in healthcare personnel
It is very uncertain whether (RCT) Safe intravenous systems changes needlestick injuries compared with regular systems (very low certainty).
2 findings from 1 review
- Devices for preventing percutaneous exposure injuries caused by needles in healthcare personnel 2017 · Cochrane Headline outcomes onlyRate ratio 0.62 [0.27, 1.41]1 study · 1 participantsVery low
- Devices for preventing percutaneous exposure injuries caused by needles in healthcare personnel 2017 · Cochrane Headline outcomes onlyRate ratio 0.06 [0, 1.09]1 study · 1 participantsVery low
(RCT) Safe intravenous systems vs regular systems
Incidences of blood contamination ‐ Active systems · preventing percutaneous exposure injuries caused by needles in healthcare personnel
(RCT) Safe intravenous systems may leads to higher incidences of blood contamination ‐ Active systems compared with regular systems (low certainty).
1 finding from 1 review
- Devices for preventing percutaneous exposure injuries caused by needles in healthcare personnel 2017 · Cochrane Headline outcomes onlyRR 1.6 [1.08, 2.36]4 studies · 961 participantsLow
(RCT) Safe intravenous systems vs regular systems
Incidences of blood contamination ‐ Passive systems · preventing percutaneous exposure injuries caused by needles in healthcare personnel
(RCT) Safe intravenous systems showed no clear difference in incidences of blood contamination ‐ Passive systems compared with regular systems (low certainty).
1 finding from 1 review
- Devices for preventing percutaneous exposure injuries caused by needles in healthcare personnel 2017 · Cochrane Headline outcomes onlyRR 0.94 [0.5, 1.75]2 studies · 528 participantsLow
(RCT) Safe intravenous systems vs regular systems
Incidence of blood leakage ‐ Active systems · preventing percutaneous exposure injuries caused by needles in healthcare personnel
(RCT) Safe intravenous systems may leads to lower incidence of blood leakage ‐ Active systems compared with regular systems (low certainty).
1 finding from 1 review
- Devices for preventing percutaneous exposure injuries caused by needles in healthcare personnel 2017 · Cochrane Headline outcomes onlyRR 0.21 [0.11, 0.37]1 study · 147 participantsLow
IVIg vs acetylsalicylic acid (ASA)
Incidence of CAAs (up to 30 days) · people undergoing initial treatment for KD
Primary treatment with intravenous immunoglobulin (IVIG) probably leads to lower incidence of CAAs (up to 30 days) compared with acetylsalicylic acid (ASA) (moderate certainty).
1 finding from 1 review
- Intravenous immunoglobulin for the treatment of Kawasaki disease 2023 · Cochrane Headline outcomes onlyOR 0.6 [0.41, 0.87]11 studies · 1437 participantsModerate
IVIg vs different infusion regimens of IVIG
Acute coronary syndrome · people undergoing initial treatment for KD
The review found no eligible studies for this question.
1 finding from 1 review
- Intravenous immunoglobulin for the treatment of Kawasaki disease 2023 · Cochrane Headline outcomes onlyno estimate extractedStudies not reportedNo studies found
IVIg vs different infusion regimens of IVIG
Duration of fever · people undergoing initial treatment for KD
1 finding from 1 review
- Intravenous immunoglobulin for the treatment of Kawasaki disease 2023 · Cochrane Headline outcomes onlyno estimate extracted4 studies · 992 participantsLow
IVIg vs different infusion regimens of IVIG
Need for extra treatment · people undergoing initial treatment for KD
Primary treatment with intravenous immunoglobulin (IVIG) may leads to lower need for additional treatment (up to 6 months) compared with different infusion regimens of IVIG (low certainty).
1 finding from 1 review
- Intravenous immunoglobulin for the treatment of Kawasaki disease 2023 · Cochrane Headline outcomes onlyOR 0.29 [0.1, 0.88]4 studies · 1125 participantsLow
IVIg vs different infusion regimens of IVIG
Duration of hospital stay MCID: 1 day absolute difference · people undergoing initial treatment for KD
1 finding from 1 review
- Intravenous immunoglobulin for the treatment of Kawasaki disease 2023 · Cochrane Headline outcomes onlyno estimate extracted3 studies · 752 participantsLow
IVIg vs different infusion regimens of IVIG
Mortality (all‐cause) (up to 7 weeks) · people undergoing initial treatment for KD
1 finding from 1 review
- Intravenous immunoglobulin for the treatment of Kawasaki disease 2023 · Cochrane Headline outcomes onlyno estimate extracted1 study · 549 participantsModerate
IVIg vs prednisolone
Incidence of CAAs (acute phase) · people undergoing initial treatment for KD
It is very uncertain whether primary treatment with intravenous immunoglobulin (IVIG) changes incidence of CAAs (acute phase) compared with prednisolone (very low certainty).
1 finding from 1 review
- Intravenous immunoglobulin for the treatment of Kawasaki disease 2023 · Cochrane Headline outcomes onlyOR 0.6 [0.24, 1.48]2 studies · 140 participantsVery low
IVIg vs prednisolone
Incidence of any adverse effects after treatment initiation ( · people undergoing initial treatment for KD
Primary treatment with intravenous immunoglobulin (IVIG) showed no clear difference in incidence of any adverse effects after treatment initiation (up to 3… compared with prednisolone (low certainty).
1 finding from 1 review
- Intravenous immunoglobulin for the treatment of Kawasaki disease 2023 · Cochrane Headline outcomes onlyOR 4.18 [0.19, 89.48]1 study · 90 participantsLow
IVIg vs prednisolone
Acute coronary syndrome · people undergoing initial treatment for KD
1 finding from 1 review
- Intravenous immunoglobulin for the treatment of Kawasaki disease 2023 · Cochrane Headline outcomes onlyno estimate extracted1 study · 90 participantsLow
IVIg vs prednisolone
Fever clearance time · people undergoing initial treatment for KD
1 finding from 1 review
- Intravenous immunoglobulin for the treatment of Kawasaki disease 2023 · Cochrane Headline outcomes onlyno estimate extracted2 studies · 140 participantsVery low